Bio-Rad's Tour de Cure National Team Raises Over $125,000

HERCULES, CA--(Marketwired - Aug 27, 2013) -  Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B), a multinational manufacturer and distributor of life science research and clinical diagnostic products, once again participated as a National Team for Tour de Cure and raised over $125,000 in the organization's cycling events that took place nationwide this year to benefit the American Diabetes Association.

Bio-Rad's National Team took part in several Tour de Cure events this year with its largest presence of over 200 riders at the Napa Valley Tour de Cure, which occurred in May. As a National Team, all donations raised by Team Bio-Rad at different Tour de Cure events throughout the year are counted together to obtain one grand total.

"We are pleased to participate as a National Team in Tour de Cure," said Bio-Rad President and CEO Norman Schwartz. "It is great to see the continued interest and support of all of the participants to make Tour de Cure such a success each year. Events such as these give us all the opportunity to help improve the lives of those inflicted with this disease." 

About Bio-Rad
Bio-Rad Laboratories, Inc. (NYSE: BIO) and (NYSE: BIO.B) has remained at the center of scientific discovery for more than 50 years, manufacturing and distributing a broad range of products for the life science research and clinical diagnostic markets. The company is renowned worldwide among hospitals, universities, major research institutions, as well as biotechnology and pharmaceutical companies for its commitment to quality and customer service. Founded in 1952, Bio-Rad is headquartered in Hercules, California, and serves more than 100,000 research and industry customers worldwide through its global network of operations. The company employs over 7,600 people globally and had revenues exceeding $2 billion in 2012. For more information, visit www.bio-rad.com.